Editas Medicine, Inc. (8EM.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:03AM CEST
| Previous Close | 5.22 |
| Open | 5.33 |
| Bid | 4.62 x N/A |
| Ask | 4.70 x N/A |
| Day's Range | 5.33 - 5.33 |
| 52 Week Range | 4.87 - 10.68 |
| Volume | |
| Avg. Volume | 57 |
| Market Cap | 442.627M |
| Beta (5Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.88 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.77 |
- Thomson Reuters StreetEvents
Q1 2024 Editas Medicine Inc Earnings Call
Q1 2024 Editas Medicine Inc Earnings Call
ZacksEditas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireEditas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines
© 2024 Yahoo. All rights reserved.